Spec­trum shares spike on pre­lim­i­nary PhII can­cer da­ta; Clin­i­pace names a new CEO

→ One of Wednes­day’s big movers was Spec­trum Phar­ma­ceu­ti­cals $SP­PI, which tout­ed the pre­lim­i­nary re­sults from a small Phase II study of its drug pozi­o­tinib in EGFR ex­on 20 mu­tant non-small cell lung can­cer. All 11 pa­tients evalu­able so far have re­spond­ed in some fash­ion, they said, spurring plans to meet with reg­u­la­tors to eval­u­ate their shot at an ac­cel­er­at­ed ap­proval.

Jeff Williams, the co-founder and CEO of the CRO Clin­i­pace World­wide is tak­ing an ex­pand­ed ad­vi­so­ry role with the com­pa­ny’s board and hand­ing over his re­spon­si­bil­i­ties to Ja­son Mon­teleone, who takes over as the new CEO.  Williams will re­main a di­rec­tor and will fo­cus on strate­gic ini­tia­tives.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.